Want to see MBRX full AI Analyst Report?
Top Page
Moleculin Biotech
(NASDAQ:MBRX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.43
▼(-29.67% Downside)
Action:Reiterated
Date:09/29/26
The score is primarily weighed down by weak financial performance (no revenue, sustained losses, and significant cash burn) and bearish technical signals (below major moving averages with negative MACD). Corporate events provide some upside from clinical progress and IP strengthening, but this is tempered by delisting risk and ongoing reliance on external funding; valuation offers limited support given negative earnings and no dividend.
Positive Factors
Late-stage clinical progress
Completing enrollment in a pivotal Phase 2/3 AML trial marks meaningful advancement for Moleculin’s lead program. The planned Part A readout can inform dose selection and determine whether development progresses, creating a defined clinical catalyst over the next several quarters.
Negative Factors
Pre-revenue and persistent losses
Moleculin remains pre-commercial, with no reported revenue and sizable recurring losses. Without sales to offset its operating cost base, profitability and operating leverage remain unproven, leaving future progress dependent on clinical execution and eventual product commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Late-stage clinical progress
Completing enrollment in a pivotal Phase 2/3 AML trial marks meaningful advancement for Moleculin’s lead program. The planned Part A readout can inform dose selection and determine whether development progresses, creating a defined clinical catalyst over the next several quarters.
Read all positive factors
Moleculin Biotech (MBRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.01M
Dividend YieldN/A
Average Volume (3M)972.57K
Price to Earnings (P/E)―
Beta (1Y)1.03
Revenue GrowthN/A
EPS Growth85.06%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-17.13
Shares Outstanding20,385,780
10 Day Avg. Volume825,830
30 Day Avg. Volume972,572
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.26
Price to Sales (P/S)0.00
P/FCF Ratio-0.17
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.11K
Enterprise Value/Ebitda-0.29
Forecast
1Y Price Target
$12.00Price Target Upside1867.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.69
Revenue Forecast (FY)N/A
Moleculin Biotech Business Overview & Revenue Model
Company Description
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergo...
Moleculin Biotech Earnings Call Summary
Earnings Call Date:May 14, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:Mar 19, 2027
Earnings Call Sentiment Positive
The earnings call reflects significant progress in clinical trials and regulatory approvals, particularly for Annamycin. New patents and drug names bolster future market positioning. However, financial constraints and potential EU approval delays pose challenges.Positive Updates
Phase 3 MIRACLE Trial Progress
The Phase 3 MIRACLE trial for Annamycin has officially started with the first patient treated, and 38 sites selected worldwide. The European Medicines Agency has approved the trial in all nine countries requested.
Negative Updates
Financial Runway and Need for Additional Funding
The company ended the quarter with $8 million in cash, which will only run operations into the third quarter of this year, necessitating a $15 million raise.
Read all updates
Q1-2025 Updates
Positive
Negative
Phase 3 MIRACLE Trial Progress
The Phase 3 MIRACLE trial for Annamycin has officially started with the first patient treated, and 38 sites selected worldwide. The European Medicines Agency has approved the trial in all nine countries requested.
Read all positive updates
Company Guidance
During the Moleculin Biotech First Quarter 2025 Update Conference Call, several key metrics and guidance were discussed. The company announced the initiation of the Phase 3 MIRACLE trial for Annamycin, with 38 sites selected globally and the first patient already treated. The European Medicines Agency provided approval for the trial across nine EU countries, marking a significant milestone. Moleculin also revealed additional patent protections for Annamycin, extending its composition of matter protection into at least 2040. They highlighted the progress of their MB-107 clinical trial for advanced soft tissue sarcoma and the investigator-sponsored trial of WP1066, which has recruited seven patients at Northwestern University. Financially, Moleculin ended the quarter with $8 million in cash and anticipates needing to raise approximately $15 million to fund operations into the first quarter of 2026. They aim to unblind data from the first 45 patients in the MIRACLE trial by the end of 2025, which they believe will be pivotal for potential new drug approval. Their market cap stands at over $14 million, with 14.1 million shares outstanding and a three-month average trading volume of nearly 6 million shares per day.Moleculin Biotech Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -8.00K | -90.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -30.21M | -33.47M | -21.64M | -29.64M | -28.89M | -15.73M |
| Net Income | -30.33M | -33.56M | -21.76M | -29.77M | -29.02M | -15.89M |
Balance Sheet | ||||||
| Total Assets | 21.09M | 22.13M | 16.93M | 38.22M | 57.42M | 84.09M |
| Cash, Cash Equivalents and Short-Term Investments | 7.26M | 8.88M | 4.28M | 23.55M | 43.15M | 70.90M |
| Total Debt | 292.00K | 359.00K | 478.00K | 574.00K | 451.00K | 159.00K |
| Total Liabilities | 9.50M | 7.12M | 10.95M | 12.14M | 5.23M | 5.10M |
| Stockholders Equity | 11.59M | 15.01M | 5.98M | 26.07M | 52.19M | 78.99M |
Cash Flow | ||||||
| Free Cash Flow | -25.36M | -22.73M | -23.88M | -24.23M | -27.71M | -18.97M |
| Operating Cash Flow | -25.36M | -22.73M | -23.86M | -24.10M | -27.64M | -18.95M |
| Investing Cash Flow | 0.00 | 0.00 | -13.00K | -124.00K | -67.00K | -19.00K |
| Financing Cash Flow | 25.09M | 27.28M | 4.63M | 4.65M | -23.00K | 74.72M |
Moleculin Biotech Technical Analysis
Negative
0.61
Price Trends
0.58
Negative
1.52
Negative
2.28
Negative
Market Momentum
-0.09
Positive
33.41
Neutral
8.90
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MBRX, the sentiment is Negative. The current price of 0.61 is above the 20-day moving average (MA) of 0.57, above the 50-day MA of 0.58, and below the 200-day MA of 2.28, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 33.41 is Neutral, neither overbought nor oversold. The STOCH value of 8.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MBRX.
Moleculin Biotech Risk Analysis
Moleculin Biotech disclosed 58 risk factors in its most recent earnings report. Moleculin Biotech reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Moleculin Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $15.35M | >-0.01 | -147.45% | ― | ― | ― | |
44 Neutral | $9.01M | -0.03 | -816.56% | ― | ― | 85.06% | |
44 Neutral | $118.91M | -0.96 | -1005.80% | 0.36% | -100.00% | 54.89% | |
43 Neutral | $53.00M | -2.68 | -47.92% | ― | -75.00% | 74.04% |
* Healthcare Sector Average
MBRX
Moleculin Biotech
0.44
-11.25
-96.22%
IBIO
Ibio
0.87
0.06
7.80%
INO
Inovio Pharmaceuticals
1.15
-1.32
-53.44%
AKTX
Akari Therapeutics
8.77
-28.91
-76.72%
LNAI
Lunai Bioworks
1.23
-8.05
-86.75%
Moleculin Biotech Corporate Events
Executive/Board ChangesShareholder MeetingsStock Split
Moleculin Biotech Shareholders Approve Key Annual Meeting Actions
Neutral
Oct 9, 2026
On October 9, 2026, Moleculin Biotech held its Annual Meeting, where shareholders elected all five nominated directors and ratified Grant Thornton LLP as the independent auditor for the year ending December 31, 2026. Investors also approved an ame...
Business Operations and StrategyRegulatory Filings and Compliance
Moleculin Biotech Updates Investors With New Presentation
Neutral
Oct 5, 2026
On October 5, 2026, Moleculin Biotech, Inc. used a new corporate presentation that was posted on its website and furnished to investors via a Form 8-K filing. The materials were explicitly designated as furnished rather than filed under U.S. secur...
Business Operations and StrategyProduct-Related Announcements
Moleculin Completes Enrollment in Pivotal AML Trial
Positive
Sep 29, 2026
On September 29, 2026, Moleculin Biotech reported it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin plus cytarabine (AnnAraC) in adults with relapsed or refractory acute myeloid leukemia, with 89 ...
Business Operations and StrategyProduct-Related Announcements
Moleculin Highlights Annamycin Cardiac Safety in New Analysis
Positive
Sep 28, 2026
On September 28, 2026, Moleculin Biotech announced that a peer-reviewed pooled analysis of Annamycin’s cardiac safety was published in Frontiers in Cardiovascular Medicine, covering 90 patients from five trials in acute myeloid leukemia and ...
Business Operations and StrategyProduct-Related Announcements
Moleculin Highlights Immune-Driven Annamycin Pancreatic Cancer Data
Positive
Sep 25, 2026
On September 25, 2026, Moleculin Biotech reported new preclinical data showing that its lead drug Annamycin (naxtarubicin) exerts antitumor activity in pancreatic cancer partly through CD8+ T cell cytotoxicity. The data, presented at the AACR Conf...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Moleculin Secures Mexican Patent Strengthening Annamycin IP Portfolio
Positive
Sep 23, 2026
On September 23, 2026, Moleculin Biotech announced that the Mexican Patent Office granted Patent No. 436849, securing protection for its lung-targeted liposomal Annamycin technology through November 23, 2040 and reinforcing its international intel...
Delistings and Listing ChangesRegulatory Filings and Compliance
Moleculin Biotech Faces Nasdaq Delisting Risk After Notice
Negative
Sep 18, 2026
On September 15, 2026, Moleculin Biotech disclosed that it had received a Nasdaq Staff Determination Letter stating its common stock failed to meet the $1.00 minimum bid price requirement over the 30 business days from July 31 to September 11, 202...
Business Operations and Strategy
Moleculin Showcases New Annamycin Data at September Conferences
Positive
Sep 14, 2026
On September 14, 2026, Moleculin Biotech announced that new data on its lead drug candidate Annamycin (naxtarubicin) would be showcased at three scientific meetings in September, including the AACR Conference on Pancreatic Cancer in San Diego. The...
Business Operations and StrategyRegulatory Filings and Compliance
Moleculin Biotech Updates Investors with New Presentation
Neutral
Aug 31, 2026
On August 31, 2026, Moleculin Biotech, Inc. used a new corporate presentation as part of its investor communications, posting the materials on its website and furnishing them to regulators. The presentation was submitted under a current report but...
Business Operations and StrategyPrivate Placements and Financing
Moleculin Biotech completes $9.3M equity financing
Positive
Aug 3, 2026
On July 31, 2026, Moleculin Biotech entered into a placement agency agreement with Roth Capital Partners for a public offering of 12,376,667 shares of common stock or pre-funded warrants, along with Series I common stock purchase warrants for up t...
Business Operations and StrategyProduct-Related Announcements
Moleculin Biotech Highlights Promising MIRACLE Trial Remission Data
Positive
Jul 31, 2026
On July 31, 2026, Moleculin reported updated preliminary blinded data from Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin plus cytarabine (AnnAraC) in relapsed or refractory AML, showing a complete remission rate of 24% and composite c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.